Human Genome Sciences Posts Widened Loss Amid Shriveled Revenue | GenomeWeb

NEW YORK, Feb. 14 - Human Genome Sciences on Thursday said that bolstered R&D to develop new drugs together with shriveled revenue brought on by the end of the Human Gene Consortium caused net losses to widen in the fourth quarter.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.